Resources

VectorBuilder and Lir Therapeutics formed a strategic collaboration to develop adeno-associated virus (AAV) capsids.

Remembering Mike Hoare, the RedX-Skye deal. Stablepharma’s fridge-free vaccine milestone, MHRA quarterly numbers, new ministerial responsibilities for UK life sciences and backing human biology-based models.

Celebrating trailblazing biotech founders

The Milner Therapeutics Institute (MTI) is proud to be part of a new £20 million Medical Research Council (MRC) investment that will establish a UK Pre-clinical Translational Models Hub.

AI may be biotech’s biggest opportunity, but without the right data infrastructure, even the smartest models risk getting stuck at pilot stage

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease

BIA Annual General Meeting 2026: nominations open for BIA Board election

Tanya Bos, Non-Executive Director at BioSci Toolkit CIC, discusses securing her first NED role as part of the She Steers programme

Join the delegation as BIA boosts UK presence at BioShanghai in September

The advantages to building a business in the UK's biotech clusters

MORF-Bio has secured an Innovate UK Investor Partnerships Award, unlocking a new investment round led by Deeptech Seed Fund and matched by Helix Research and Enterprise.

Last month, the multi-award-winning Advanced Therapies Apprenticeship Community (ATAC) welcomed its 400th member. 

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

Chris Molloy on new pension scale-up fund news, member news from Touchlight, the major GSK investment in Cambridge, a valuable collaboration for Relation and BIA's parliamentary engagement

Aravax today announces it has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead product, PVX108 for the treatment of peanut allergy.

NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce the appointment of Claus Sundgreen M.D. as chief medical officer (CMO), effective 1 August 2026.

Biosolutions are a billion-pound national asset delivering growth in every region of the UK

Find out more about a free, independent review of R&D tax claims for BIA members.

Touchlight announced the first UK patient was dosed with a bespoke cancer vaccine manufactured using its proprietary dbDNA technology.